A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors
A phase 1/2 trial of CGT4859 in biliary tract cancer, run by Cogent Biosciences, Inc., active and no longer recruiting.
Overview
A Study of an FGFR2/3 Inhibitor (CGT4859) in Patients With Cholangiocarcinoma and Other Advanced Solid Tumors is a phase 1/2 interventional study registered as NCT06777316 by Cogent Biosciences, Inc., with 110 participants enrolled, started 2025-01-22 and due to reach its primary completion in 2027-03. Interventions recorded: CGT4859.
Similar pages
not linked directly; found by shared links- TrialA Study of ICP-192 in Patients With FGFR2-Rearranged Unresectable or Metastatic Intrahepatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study to Select a Dose Regimen (Part A) and to Investigate Overall Survival (Part B) With Nanvuranlat Compared With Physician's Best Choice in Participants Aged 18 Years or Older With Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialPhase I/II Study: Allogeneic NK-cell Therapy With Chemotherapy for Post-Surgery PDA or Cholangiocarcinoma Patients
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of SHR-A1904 in Previous Systemic Treatment Failed Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialA Study of AK130 in Combination With AK112 for the Treatment of Advanced Biliary Tract Cancer
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialCombination of GNS561 and Trametinib in Patients With Advanced KRAS Mutated Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialAn Early Access Study of Ivosidenib in Patients With a Pretreated Locally Advanced or Metastatic Cholangiocarcinoma
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.
- TrialStudy of Futibatinib in Patients With Advanced Cholangiocarcinoma With FGFR2 Fusion or Rearrangement
Shares Biliary tract cancer (cholangiocarcinoma) and the tag pipeline.